Top 3 drug approvals in oncology in June: Yescarta®, Lynparza® and Mekinist®

Tafinlar® (dabrafenib) + Mekinist® (trametinib) Approved: 23 June 2022 Approving body: US FDA Indication: BRAF V600E solid tumors One of the prominent approvals to take place in June was for a drug combination targeting a number of solid tumors. Tafinlar plus Mekinist was granted accelerated approval by the US FDA for the treatment of adult and pediatric patients with unresectable/ metastatic solid tumors with BRAF V600E mutation. The approval could open up treatment options for over 20 tumor types “Physicians should consider a BRAF test as a routine diagnostic step that could enable a new option for treating patients with...